# Genetic predisposition of patients with vestibulodynia (chronic pain around the opening of the vagina): a case-control study

Submission date	Recruitment status  No longer recruiting	<ul><li>Prospectively registered</li></ul>		
10/07/2023		[X] Protocol		
Registration date	Overall study status Completed Condition category	Statistical analysis plan		
29/07/2023		Results		
Last Edited		Individual participant data		
24/07/2023	Urological and Genital Diseases	Record updated in last year		

# Plain English summary of protocol

Background and study aims

Vulvodynia is a highly prevalent form of chronic genital pain in women, to such an extent that prevalence studies estimate ranges from 10% to 28% in reproductive-aged women. Localized provoked vulvodynia at the vestibule, known as vestibulodynia (VBD), is the most common manifestation of the disease (about 80%). Women with VBD often describe vulvar pain as burning, stinging, irritation, rawness, and dyspareunia (difficult or painful intercourse). VBD represents a summation and overlapping of various trigger factors (infections, hormonal disturbances, allergies, genetic aspects, psychological vulnerability, and others) with weight and predominance varying from patient to patient. The study aims to develop a specific test to identify earlier the most susceptible subjects to develop VBD and build a preventive strategy to avoid the development and/or chronicity of the disease. Further, data will be obtained to cluster patients to tailor the most appropriate treatment.

# Who can participate?

Adult patients with VBD aged 18 to 45 years old compared with a healthy control group

# What does the study involve?

Outcomes include features and correlations in VBD patients in comparison with the control group using:

- 1. Shallow whole genome sequencing of DNA obtained from a blood sample
- 2. Vestibular microbiome asset obtained from a vestibular sample

What are the possible benefits and risks of participating?

Participants may benefit from the future development of a specific test to identify the most susceptible subjects earlier and from the preventive strategy to avoid the development and/or chronicity of the disease. Patients will also benefit from being clustered into groups for the most appropriate treatment. There are no risks of participating in the study. The vestibular sample is related to vaginal secretion for microbiome analysis and is not a biopsy.

Where is the study run from? Lower Genital Tract Disease Unit, Vittore Buzzi Hospital (Italy)

When is the study starting and how long is it expected to run for? March 2023 to September 2023

Who is funding the study?

Associazione Italiana Vulvodinia, a non-profit Italian association whose mission is to improve the health and quality of life of women experiencing vulvodynia and chronic vulvar pain (Italy)

Who is the main contact? Prof Filippo Murina, filippo.murina@unimi.it

# **Contact information**

# Type(s)

Principal investigator

### Contact name

Prof Filippo Murina

### **ORCID ID**

https://orcid.org/0000-0002-9966-6448

## Contact details

Chief of Lower Genital Tract Disease Unit
Obst. and Gyn. Dept.- Vittore Buzzi Hospital-Milan-Italy (Via Castelvetro 32-Milan)
Adjunct Professor Università degli Studi
Scientific Director Vulvodynia Italian Association
Milan
Italy
20124
+393386287765
filippo.murina@unimi.it

# Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

SDSM-2022-01.1

# Study information

### Scientific Title

Genomic evaluation of patients with vestibulodynia: a case-control study

# **Acronym**

VeGA Study (Vestibulodynia-Genomic-Assessing)

# **Study objectives**

The Research Hypothesis for the present study is to prospectively compare four main parameters that we consider essential in developing vestibulodynia (VBD):

- 1. Increased sensitivity to pain
- 2. Inflammatory state
- 3. Hormonal asset
- 4. Microbiological pattern

Our aim is to develop a specific test to identify the most susceptible subjects who develop VBD earlier and build a preventive strategy to avoid the development and/or chronicity of the disease. Furthermore, an objective is to collect data in order to cluster patients and customize the most suitable treatment for each individual.

# Ethics approval required

Ethics approval required

# Ethics approval(s)

approved 03/05/2023, V. Buzzi Hospital (Via Castelvetro 24, Milan, 20124, Italy; +39 (0) 257995420; info@asst-fbf-sacco.it), ref: 112/VT/2023

# Study design

Case-control study

# Primary study design

Observational

# Study type(s)

Diagnostic

# Health condition(s) or problem(s) studied

Localized provoked vulvodynia at the vestibule, known as vestibulodynia (VBD)

### **Interventions**

This is a case-control study in women with vestibulodynia (VBD). All women aged 18 years and before menopause, (cessation of menstruation for 12 months) with VBD that will present to our unit on lower genital tract disease will be invited to participate. The control group will include healthy fertile asymptomatic women without any vulvovaginal conditions that will attend the study hospital for cervical cancer screening programs. It is expected this investigator-initiated research study will be completed approximately 6 months following initial approval by the Institutional Ethical Board.

The study team will analyze DNA obtained from a blood sample of patients with VBD compared with a healthy control group, using the technique of Shallow Genome Sequencing (SGS), which is a new and high-throughput technology to achieve genome-wide single nucleotide polymorphisms (SNPs) genetic variation accurately.

Evaluation of current perception threshold (CPT) is a technique which quantifies the sensitivity of vestibular nerve fibers. The CPT values will be measured using the Neurometer CPT/C

electrodiagnostic neurostimulator (Neurotron, Inc., Baltimore, MD), which emits constant alternating sinusoid waveform current stimuli at frequencies of 2000 Hz (specific for large, myelinated Ab fibers), 250 Hz (specific for Ad fibers), and 5Hz (specific for C fibers), at intensity levels from 0.001 to 9.99mA.

# Clinical procedures:

Candidates for enrollment will be screened within 15 days prior to enrollment. Before initiation of any test procedures, Subjects will be fully informed of the study plan, procedures, and risks involved in participating in the study. Each potential Subject will be required to read and indicate her understanding by signing and dating the ICF prior to the initiation of any screening procedures. Screening procedures will consist of the following:

- Physical examination and medical history will be collected
- Evaluation of symptoms: 0–10-point visual scale (VAS) related to dyspareunia and vulvovaginal pain/burning, only in the VBD group
- Vulvoscopy with an evaluation of vestibular cotton swab test
- Taking blood samples for DNA analysis (about 3ml)
- Taking vaginal secretion at the vestibular site for microbiome analysis
- Assessment of vestibular CPT evaluation using the Neurometer CPT/C, electrodiagnostic neurostimulator
- Vestibular mucosa thickness performed by ultrasound measurements (B-Scan) with a 20 MHz validated system (Derma Scan C, Cortex Technology, Denmark), producing cross-sectional images of the skin down to a depth of approximately 15 mm
- Assessment of vaginal EMG measurements, collected at states of rest and during several exercises of the pelvic floor through an EMG device with a vaginal sensor (Myotonus plus@-London-UK)

# **Intervention Type**

Genetic

# Primary outcome(s)

- 1. DNA patterns obtained from a blood sample measured using Shallow Genome Sequencing at baseline
- 2. Vestibular microbiome asset obtained from a vestibular sample measured using complex analysis using 16sRNA technique at baseline

# Key secondary outcome(s))

- 1. Vulvar vestibule current perception threshold (CPT) values (1=0.01 mA) measured using a G-trode Vaginal/Rectal Electrode (Neurotron, Inc., Baltimore, MD) at baseline
- 2. Vestibular mucosa thickness measured using ultrasound measurements (B-Scan) with a 20 MHz validated system (Derma Scan C, Cortex Technology, Denmark), producing cross-sectional images of the skin down to a depth of approximately 15 mm at baseline
- 3. Vaginal electromyography (EMG) measured at rest and during several exercises of the pelvic floor using an EMG device with a vaginal sensor (Myotonus plus@-London-UK) at baseline

# Completion date

15/09/2023

# **Eligibility**

Key inclusion criteria

- 1. Women aged at least 18 years old and before menopause (absence of menstruation for 12 months)
- 2. Experience moderate to severe pain (minimum of 5/10 on a numerical rating scale in at least 90 % of attempted sexual intercourse) for the VBD group
- 3. Pain limited to the vestibule during vaginal intercourse and during activities exerting pressure on the vestibule (tampon insertion, tight jeans or pants, cycling, horseback riding) for VBD group
- 3. Presence of VBD for at least 3 months and diagnosed according to the standardized gynecological examination protocol by one of our staff gynecologists
- 4. Have a stable sexual partner (sexual activity should include some attempted vaginal penetrations to evaluate pain intensity)
- 5. Subject is willing to attempt sexual activity between visits
- 6. Read and signed informed consent

# Participant type(s)

Healthy volunteer, Patient

# Healthy volunteers allowed

No

# Age group

Adult

# Lower age limit

18 years

# Upper age limit

45 years

### Sex

Female

# Key exclusion criteria

- 1. Active vulvovaginal infections at the time of their gynecological examination
- 2. Genital bleeding of unknown origin
- 3. Unwillingness to provide informed consent to the trial
- 4. Women with concomitant vulvar dermatosis or other vulvar disorders
- 5. Symptoms or signs in the past related to VBD, only for the Control group

# Date of first enrolment

15/05/2023

### Date of final enrolment

30/08/2023

# Locations

# Countries of recruitment

Italy

# Study participating centre V.Buzzi Hospital

Via Castelvetro 24 Milan Italy 20124

# **Sponsor information**

# Organisation

Associazione Italiana Vulvodinia Onlus

## **ROR**

https://ror.org/03kj3qm29

# Funder(s)

# Funder type

Research organisation

### **Funder Name**

Associazione Italiana Vulvodinia

# **Results and Publications**

# Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Prof Filippo Murina, filippo.murina@unimi.it. Overall data and statistical analysis will be available from October 2023. Consent from participants will be required and obtained.

# IPD sharing plan summary

Stored in non-publicly available repository, Available on request

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Protocol file			24/07/2023	No	No